BAY43-9006 - Phase II in Advanced Breast Cancer
NCT00101400
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasms
Breast Cancer
Interventions
DRUG:
Sorafenib (Nexavar, BAY43-9006)
Sponsor
Bayer